THE THERAPEUTIC POTENTIAL OF EXOSOMES

• The Therapeutic Potential Of Exosomes

  In this Cell & Gene Live, Dr. Maria Mitrani, Co-Founder and Chief Scientific Officer at Organicell; Benny Sorensen, Scientific Advisory Board member at Codiak BioScience; and Nicolas Rousseau, Co-Founder and COO at EVerZom talk to Chief Editor Erin Harris about the sector’s understanding of extracellular vesicles (EV). Specifically, they cover the regulatory landscape for exosomes as well as appropriate characterization models and advancements in manufacturing needed to ensure scalability. The expert panelists also provided detailed responses to audience questions submitted during the live event. 

• What Is The Therapeutic Potential Of Exosomes?
• The Regulatory Pathway & The Road to FDA Approval
• Understanding Appropriate Characterization Methods
• Advancements In Manufacturing
• Exosomes And Scalability Challenges
• Audience Q&A

TACKLING THE CELL & GENE MANUFACTURING TALENT CRUNCH

• Tackling The Cell & Gene Manufacturing Talent Crunch

  Join Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury for a discussion with BioProcess Online Chief Editor Matt Pillar to address solutions to the biotherapeutic and cell and gene therapy process and manufacturing talent gap.

CAN INNOVATION DRIVE DOWN CELL THERAPY MANUFACTURING COSTS?

• Can Innovation Drive Down Cell Therapy Manufacturing Costs?

  The high cost of producing new cell and gene therapies is one of the largest issues facing the industry. After launching Kymriah and Yescarta, Novartis’ price tags were $475,000 and $375,000, respectively. Advancements in manufacturing are driving costs down, but not at the required pace.

• The Why Behind The Expense Of Cell Therapy Manufacturing
• The Current Challenges Facing Cell Therapy Manufacturing
• Cell Therapy Manufacturing And Economies Of Scale
• How Automation Drives Down Cell Therapy Manufacturing Costs
• True Innovations In Driving Down Cell Therapy Manufacturing

THE FUTURE OF CRISPR-ENGINEERED STEM CELL THERAPIES

• The Future of CRISPR-Engineered Stem Cell Therapies

  To learn more about CRISPR gene editing, Cell and Gene Chief Editor, Erin Harris, sat down with Sadik Kassim, Chief Technical Officer at Vor Biopharma to discuss the benefits of CRISPR-engineered stem cell therapies, the challenges and feasible solutions, what’s next, and more.

• The History of CRISPR Gene Edited Therapies
• The Future of CRISPR-Engineered Stem Cell Therapies: 3 Clinical Trial Examples
• The Ethical Implications Of Editing A Genome
• The Challenges Associated With CRISPR Gene Editing
• The Patient Perspective Of CRISPR-Engineered Stem Cell Therapies
• The Future of CRISPR-Engineered Stem Cell Therapies: Adverse Effects In Clinical Trials
• The Future of CRISPR-Engineered Stem Cell Therapies: Technology & Platforms
• The Permanency Of Gene Therapy
• The Future of CRISPR-Engineered Stem Cell Therapies: Digestive Disease Studies
• The Misconceptions Of CRISPR Gene Edited Stem Cell Therapies
• Will CRISPR Change Modern Medicine?
• The Future of CRISPR-Engineered Stem Cell Therapies: Outsourcing vs. In-House
• What The Gene Therapy Sector Doesn't Understand About CRISPR?
• The Future of CRISPR-Engineered Stem Cell Therapies: Virtual Event Audience Q&A